Early Screening and Treatment of Heart Complication in Sickle Cell Disease
About this study
This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.
- Condition
- Sickle Cell Disease
- Tested
- Deferoxamine, Deferasirox, Deferiprone, Echocardiography, Electrocardiogram (ECG)
- Sponsor
- Inova Health Care Services
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 9
- Minimum age: 18 years
- Study condition: Sickle Cell Disease
- At least 18 years of age
- Diagnosis of sickle cell disease (any genotype)
- Serum ferritin levels ≥ 400 ng/mL (up to 80 patients), or less than 400 ng/mL in those who have cardiac symptoms including shortness of breath and lower extremity edema (up to 20 patients)
- Willingness to undergo regular imaging (echocardiograms, ECG, cardiac MRI)
- ECOG performance status of 0-1
- Able to read, understand and provide written informed consent
- Deemed appropriate for participation by the treating physician
Exclusion 10
- Unable to schedule and required follow-up visits
- Medical comorbidities including:
- Known heart failure
- Unstable angina
- Uncontrolled dysrhythmias
- Acute pulmonary embolism
- Active infection or severe comorbid conditions that in the view of the investigator would limit participation
- History of hypersensitivity or contraindication to chelation therapy
- Severe renal or hepatic impairment
- Pregnancy of breastfeeding
Where
2 sites, 2 recruiting
Inova Schar Cancer
Fairfax, Virginia, United States
Inova Health Care Service
Falls Church, Virginia, United States
Contact
-
Keary Jane't
571-472-3173 keary.jane't@inova.org
-
Elahe Mollapour
571-472-0615 elahe.mollapour@inova.org
Potential match only. Final eligibility is determined by the study team.